Oladapo O. Yeku

Oncology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Journal: Nature reviews. Clinical oncology

Published: May 18, 2026

Extracellular vesicles facilitate the horizontal transfer of drug resistance and stem-like properties between ovarian tumor cells.

Extracellular vesicles facilitate the horizontal transfer of drug resistance and stem-like properties between ovarian tumor cells.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

Journal: International journal of molecular sciences

Published: December 03, 2025

First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma.

First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: November 26, 2025

First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma.

First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 14, 2025

Author Correction: Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion.

Author Correction: Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion.

Journal: Nature communications

Published: June 30, 2025

CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer.

CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer.

Journal: Frontiers in pharmacology

Published: June 21, 2025

Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

Journal: JCO precision oncology

Published: April 10, 2025

ABL1-mediated tyrosine phosphorylation of SYCP2 contributes to transcription-coupled homologous recombination and platinum resistance in ovarian cancer.

ABL1-mediated tyrosine phosphorylation of SYCP2 contributes to transcription-coupled homologous recombination and platinum resistance in ovarian cancer.

Journal: NAR cancer

Published: April 09, 2025

Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

Journal: Signal transduction and targeted therapy

Published: March 16, 2025

Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.

Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.

Journal: Gynecologic oncology

Published: February 22, 2025

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.

Journal: Journal for immunotherapy of cancer

Published: February 03, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026